請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76830完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 張琳巧(Lin-Chau Chang) | |
| dc.contributor.author | Yi-Hsuan Chiang | en |
| dc.contributor.author | 江奕璇 | zh_TW |
| dc.date.accessioned | 2021-07-10T21:38:05Z | - |
| dc.date.available | 2021-07-10T21:38:05Z | - |
| dc.date.copyright | 2021-02-25 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-02-05 | |
| dc.identifier.citation | Amur, S., LaVange, L., Zineh, I., Buckman-Garner, S., Woodcock, J., 2015. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Ther, 98(1), 34–46. Aragonès, G., Auguet, T., Berlanga, A., Guiu-Jurado, E., Martinez, S., Armengol, S., Sabench, F., Ras, R., Hernandez, M., Aguilar, C., Colom, J., Sirvent, J. J., Del Castillo, D., Richart, C., 2016. Increased circulating levels of alpha-ketoglutarate in morbidly obese women with non-alcoholic fatty liver disease. PLoS One, 11(4), e0154601. Beger, R. D., Colatsky, T., 2012. Metabolomics data and the biomarker qualification process. Metabolomics, 8(1), 2–7. Beger, R. D., Sun, J., Schnackenberg, L. K., 2010. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol, 243(2), 154–166. Bénichou C., 1990. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol, 11(2), 272–276. Benitez, L. L., Carver, P. L., 2019. Adverse effects associated with long-term administration of azole antifungal agents. Drugs, 79(8), 833–853. Björnsson E., 2010. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther, 32(1), 3–13. Boyer J. L., 2013. Bile formation and secretion. Compr Physiol, 3(3), 1035–1078. Caines, A., Moonka, D., 2020. Drug hepatotoxicity: causality assessment. Clin Liver Dis, 24(1), 25–35. Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., Monk, B. C., 2009. Efflux-mediated antifungal drug resistance. Clin Microbiol Rev, 22(2), 291–321. Castón-Osorio, J. J., Rivero, A., Torre-Cisneros, J., 2008. Epidemiology of invasive fungal infection. Int J Antimicrob Agents, 32 Suppl 2, S103–S109. Chen, C., Krausz, K. W., Shah, Y. M., Idle, J. R., Gonzalez, F. J., 2009. Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol, 22(4), 699–707. Church, R. J., Kullak-Ublick, G. A., Aubrecht, J., Bonkovsky, H. L., Chalasani, N., Fontana, R. J., Goepfert, J. C., Hackman, F., King, N., Kirby, S., Kirby, P., Marcinak, J., Ormarsdottir, S., Schomaker, S. J., Schuppe-Koistinen, I., Wolenski, F., Arber, N., Merz, M., Sauer, J. M., Andrade, R. J., van Bömmel, F., Poynard, T., Watkins, P.B., 2019. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology, 69(2), 760–773. Church, R. J., Watkins, P. B., 2019. Serum biomarkers of drug-induced liver injury: Current status and future directions. J Dig Dis, 20(1), 2–10. CTCAE, 2017. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50 (accessed 21 December 2020) Danan, G., Benichou, C., 1993. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol, 46(11), 1323–1330. Davies, K., 2000. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB life, 2000, 50(4‐5), 279–289. DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., Thompson, C. B., 2007. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A, 104(49), 19345–19350. den Hollander, J. G., van Arkel, C., Rijnders, B. J., Lugtenburg, P. J., de Marie, S., Levin, M. D., 2006. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother, 57(6), 1248–1250. Dolton, M. J., Ray, J. E., Chen, S. C., Ng, K., Pont, L. G., McLachlan, A. J., 2012. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother, 56(9), 4793–4799. European Medicines Agency, 2013. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-suspension-marketing-authorisations-oral-ketoconazole/ (accessed 9 December 2020) Fisi, V., Miseta, A., Nagy, T., 2017. The role of stress-induced O-GlcNAc protein modification in the regulation of membrane transport. Oxid Med Cell Longev, 2017, 1308692. Food and Drug Administration, 2013. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-usage-nizoral-ketoconazole-oral-Tablets-due-potentially/ (accessed 9 December 2020) Fu, S., Wu, D., Jiang, W., Li, J., Long, J., Jia, C., Zhou, T., 2020. Molecular biomarkers in drug-induced liver injury: challenges and future perspectives. Front Pharmacol, 10, 1667. García-Cortés, M., Lucena, M. I., Pachkoria, K., Borraz, Y., Hidalgo, R., Andrade, R. J., Spanish Group for the Study of Drug-induced Liver Disease (grupo de Estudio para las Hepatopatías Asociadas a Medicamentos, Geham), 2008. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther, 27(9), 780–789. Garcia-Cortes, M., Robles-Diaz, M., Stephens, C., Ortega-Alonso, A., Lucena, M. I., Andrade, R. J., 2020. Drug induced liver injury: an update. Arch Toxicol, 94(10), 3381–3407. Giannini, E. G., Testa, R., Savarino, V., 2005. Liver enzyme alteration: a guide for clinicians. CMAJ, 172(3), 367–379. Gowda, G. A., Zhang, S., Gu, H., Asiago, V., Shanaiah, N., Raftery, D., 2008. Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn, 8(5), 617–633. Hamada, Y., Ueda, T., Miyazaki, Y., Nakajima, K., Fukunaga, K., Miyazaki, T., Nakada-Motokawa, N., Nagao, M., Kawamura, H., Shigemi, A., Ebihara, F., Kimura, T., Ikegame, K., Uchino, M., Ikeuchi, H., Takesue, Y., 2020. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: a multicentre study conducted in Japan. Mycoses, 63(8), 779–786. Han, D., Shinohara, M., Ybanez, M. D., Saberi, B., Kaplowitz, N., 2010. Signal transduction pathways involved in drug-induced liver injury. Handb Exp Pharmacol, (196), 267–310. Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J. W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., Sylvester, R., Rubin, R. H., Wingard, J. R., Stark, P., Durand, C., Caillot, D., Thiel, E., Chandrasekar, P. H., Hodges, M. R., Schlamm, H. T., Troke, P.F., de Pauw, B., Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347(6), 408–415. Institute of Medicine, 2010. Micheel, C.M., Ball, J.R., (Eds.) Evaluation of biomarkers and surrogate endpoints in chronic disease. National Academies Press, Washington. Available from: https://www.ncbi.nlm.nih.gov/books/NBK220297/ doi: 10.17226/12869 (accesses 21 December 2020) Jin, H., Wang, T., Falcione, B. A., Olsen, K. M., Chen, K., Tang, H., Hui, J., Zhai, S., 2016. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother, 71(7), 1772–1785. Kwo, P. Y., Cohen, S. M., Lim, J. K., 2017. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol, 112(1), 18–35. Kyriakidis, I., Tragiannidis, A., Munchen, S., Groll, A. H., 2017. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf, 16(2), 149–165. Larrey, D., 2002. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis, 22(2), 145–155. Legendre, F., MacLean, A., Appanna, V. P., Appanna, V. D., 2020. Biochemical pathways to α-ketoglutarate, a multi-faceted metabolite. World J Microbiol Biotechnol, 36(8), 123. Liu, P., Mould, D. R., 2014. Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob Agents Chemother, 58(8), 4727–4736. Lo Re, V., 3rd, Carbonari, D. M., Lewis, J. D., Forde, K. A., Goldberg, D. S., Reddy, K. R., Haynes, K., Roy, J. A., Sha, D., Marks, A. R., Schneider, J. L., Strom, B. L., Corley, D. A., 2016. Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. Am J Med, 129(3), 283–91.e5. Lopez‐Raton M, Cadarso‐Suarez C, Rodriguez‐Alvarez MX, Gude‐Sampedro F., 2014. OptimalCutpoints: an R package for selecting optimal cutpoints in diagnostic tests. J Stat Softw, 61(8), 1–36. McGill, M. R., Jaeschke, H., 2018. Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation. Expert Rev Mol Diagn, 18(9), 797–807. Miljkovic, M. M., Dobric, S., Dragojevic-Simic, V., 2012. Accuracy and reproducibility of two scales in causality assessment of unexpected hepatotoxicity. J Clin Pharm Ther, 37(2), 196–203. Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., Greenblatt, D. J., 1981. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 30(2), 239–245. National Institute of Diabetes and Digestive and Kidney Diseases, 2017. Voriconazole. https://www.ncbi.nlm.nih.gov/books/NBK547891/ (accessed 22 December 2020) National Institute of Diabetes and Digestive and Kidney Diseases, 2019. Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. https://www.ncbi.nlm.nih.gov/books/NBK548069/ (accessed 15 January 2021) National Institute of Diabetes and Digestive and Kidney Diseases, 2019. Roussel Uclaf Causality Assessment Method (RUCAM) in drug induced liver injury. https://www.ncbi.nlm.nih.gov/books/NBK548272/ (accessed 15 January 2021) Pannala, V. R., Estes, S. K., Rahim, M., Trenary, I., O'Brien, T. P., Shiota, C., Printz, R. L., Reifman, J., Oyama, T., Shiota, M., Young, J. D., Wallqvist, A., 2020. Mechanism-based identification of plasma metabolites associated with liver toxicity. Toxicology, 441, 152493. Pfizer Inc., 2020. VFend (voriconazole) package insert. New York. https://www.pfizermedicalinformation.com/en-us/vfend/ (accessed 9 December 2020) Raschi, E., Poluzzi, E., Koci, A., Caraceni, P., Ponti, F. D., 2014. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol, 6(8), 601–612. Reshetnyak V. I., 2013. Physiological and molecular biochemical mechanisms of bile formation. World J Gastroenterol, 19(42), 7341–7360. Rodríguez-Gallego, E., Guirro, M., Riera-Borrull, M., Hernández-Aguilera, A., Mariné-Casadó, R., Fernández-Arroyo, S., Beltrán-Debón, R., Sabench, F., Hernández, M., del Castillo, D., Menendez, J. A., Camps, J., Ras, R., Arola, L., Joven, J., 2015. Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease. Int J Obes, 39(2), 279–287. Scott, L. J., Simpson, D., 2007. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs, 67(2), 269–298. Silvestro, L., Tarcomnicu, I., Savu, S. R., 2013. Matrix effects in mass spectrometry combined with separation methods — comparison HPLC, GC and discussion on methods to control these effects. In Coelho, A. V., de Matos Ferraz Franco, C. (Eds.). Tandem mass spectrometry: molecular characterization. IntechOpen, London. Senior, J. R., 2009. Monitoring for hepatotoxicity: what is the predictive value of liver 'function' tests? Clin Pharmacol Ther, 85(3), 331–334. Shao, P. L., Huang, L. M., Hsueh, P. R., 2007. Recent advances and challenges in the treatment of invasive fungal infections. 2007. Int J Antimicrob Agents, 30(6), 487–495. Sing T, Sander O, Beerenwinkel N, Lengauer T., 2005. ROCR: Visualizing classifier performance in R. Bioinformatics, 21(20), 3940–3941. Sorbi, D., McGill, D. B., Thistle, J. L., Therneau, T. M., Henry, J., Lindor, K. D., 2000. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol, 95(11), 3206–3210. Stoll, B., McNelly, S., Buscher, H. P., Häussinger, D.,1991. Functional hepatocyte heterogeneity in glutamate, aspartate and alpha-ketoglutarate uptake: a histoautoradiographical study. Hepatology, 13(2), 247–253. Tverdek, F. P., Kofteridis, D., Kontoyiannis, D. P., 2016. Antifungal agents and liver toxicity: a complex interaction. Expert Rev Anti Infect Ther, 14(8), 765–776. USFDA, 2018. Biomarker qualification: evidentiary framework. Guidance for industry and FDA Staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biomarker-qualification-evidentiary-framework. (accessed 22 December 2020) USFDA, 2020. Drugs@FDA: FDA-Approved Drugs https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process ApplNo=021266 (accessed 23 December 2020) Wu, N., Yang, M., Gaur, U., Xu, H., Yao, Y., Li, D., 2016. Alpha-ketoglutarate: physiological functions and applications. Biomol Ther, 24(1), 1–8. Wu, S. L., Cheng, C. N., Wang, C. C., Lin, S. W., Kuo, C. H., 2020. Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress. Toxicol Appl Pharmacol, 403, 115157. Wu, S. L., Wei, T. Y., Lin, S. W., Su, K. Y., Kuo, C. H., 2019. Metabolomics investigation of voriconazole-induced hepatotoxicity in mice. Chem Res Toxicol, 32(9), 1840–1849. Zhang, A., Sun, H., Yan, G., Han, Y., Ye, Y., Wang, X., 2013. Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. Clin Chim Acta, 418, 86–90. Zimmerman H. J., 1968. The spectrum of hepatotoxicity. Perspect Biol Med, 12(1), 135–161. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76830 | - |
| dc.description.abstract | Voriconazole屬於第二代triazole類藥物，經常使用在具有血液疾病的病人以治療或預防黴菌感染，由voriconazole引起的肝臟損傷從轉胺酶濃度短暫升高到肝臟機能不良都可能發生。儘管傳統的肝臟功能檢測與因果推論的評分表是評估是否為藥物引起肝臟損傷的標準流程，但仍需具更高敏感度及特異性的生物標記。代謝體分析研究指出voriconazole引起肝臟損傷的機轉與氧化壓力有關。其中，tryptophan、cytidine、inosine、pyruvate、α-ketoglutarate、glycocholate、和β-N-acetylglucosamine這7個代謝物的濃度，在voriconazole引起肝臟損傷的病人組別中具有顯著的變化。將α-ketoglutarate、glycocholate、和β-N-acetylglucosamine作為一組檢測的套組時，比傳統的肝功能檢測有更好的偵測voriconazole引起肝損傷的效果，有潛力作為生物標記。本篇研究目的在於以更多的人數 (樣本數=129) 評估該生物標記之應用潛力。我們將2016年1月1日至2017年9月30日於臺大醫院接受voriconazole療法的病人，經納入及排除條件篩選後，根據Common Terminology Criteria for Adverse Events (CTCAE) 傳統的肝功能檢測指標之濃度標準，分為控制組與產生Grade 2以上之肝毒性組別。利用液相層析四極柱質譜儀分析病人血漿檢體的上述目標代謝物，將得到的代謝物層析峰面積 (peak area) 進行統計學上的差異倍數評估、單變項統計以及多變項羅吉斯迴歸。有肝毒性組別與控制組的病人，其血中α-ketoglutarate和glycocholate濃度都呈現顯著的差異。由α-ketoglutarate和glycocholate作為一組檢測套組後對於肝損傷的偵測能力也高於傳統的肝功能檢測。以1.250為分界值偵測肝毒性時，具有78.6%的敏感度與72.4%的特異性。然而，由於本研究難以使用傳統因果推論評量評估表篩選因voriconazole引起肝臟損傷的病人，因此，未來需利用更多經評估表篩選後，確認為voriconazole引起肝臟損傷的病人進行研究，以進一步證實α-ketoglutarate及glycocholate作為voriconazole引起肝臟損傷生物標記之適用性。 | zh_TW |
| dc.description.abstract | Voriconazole is a second-generation triazole. It is commonly used for prophylaxis and treatment of fungal infections in hematology patients. Voriconazole-induced liver injury has been reported from transient elevation in serum aminotransferase levels to severe hepatic dysfunction. Although conventional liver tests and scoring systems of causality were currently the standard assessment for drug-induced liver injury (DILI), ideal biomarkers with higher sensitivity and specificity were still in need. Voriconazole-induced liver injury was shown to be associated with oxidative stress by using metabolomics analysis. Levels of seven metabolites, including tryptophan, cytidine, inosine, pyruvate, α-ketoglutarate, glycocholate, and β-N-acetylglucosamine, were significantly changed in patients with voriconazole-induced liver injury. A metabolite panel consisting of α-ketoglutarate, glycocholate, and β-N-acetylglucosamine was previously proposed as potential biomarkers to identify voriconazole-induced liver injury with better performance than that of conventional liver tests. The present study aimed to evaluate the practicality of these biomarkers in a larger number of patients (n=129). After application of the inclusion and exclusion criteria, patients receiving voriconazole therapy at the National Taiwan University Hospital from 1 January 2016 to 30 September 2017 were categorized into the control group and the hepatotoxicity group (with at least Grade 2 adverse events) based on the levels of liver tests according to the Common Terminology Criteria for Adverse Events (CTCAE). The analysis of plasma samples for the aforementioned metabolites by ultra-high-performance liquid chromatography coupled to triple quadrupole mass spectrometry was performed. The obtained peak areas of metabolites were analyzed for fold change evaluation, univariate statistics, and multivariate logistic regression. Levels of α-ketoglutarate and glycocholate were significantly different between the control group and the hepatotoxicity group. The panel consisting of the two metabolites also had better performance for detecting liver injury in comparison with the individual biomarkers in the conventional liver tests. With the cutoff value of 1.250, the sensitivity and specificity to identify hepatotoxicity were 78.6% and 72.4%, respectively. However, there was difficulty in the application of conventional scales for the identification of patients with voriconazole-induced liver injury in the present study. Therefore, further investigation with more patients meeting the “probable” criteria of voriconazole-induced liver injury is needed for confirming the suitability of α-ketoglutarate and glycocholate as the biomarkers for voriconazole-induced liver injury. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-10T21:38:05Z (GMT). No. of bitstreams: 1 U0001-0502202114375700.pdf: 2647872 bytes, checksum: 103df22614d4cc8ddf6018d25f3617e3 (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 口試委員會審定書 ··································································i 誌謝 ·············································································ii 中文摘要··········································································iii Abstract ········································································v Table of Contents ·······························································vii List of Figures ·································································ix List of Table ···································································x CHAPTER 1 Introduction ······················································1 1.1 Voriconazole and its hepatotoxicity ·······································2 1.2 Challenges in the diagnosis of drug-induced liver injury ··················5 1.3 Biomarkers for drug-induced liver injury ··································13 1.4 Metabolomics studies in the investigation of drug-induced hepatotoxicity ··15 CHAPTER 2 Aims ······························································17 CHAPTER 3 Materials and Methods ·············································18 3.1 Study Design ······························································18 3.2 Definition of Voriconazole-Induced Hepatotoxicity ·························20 3.3 Analyses for Target Metabolites ···········································22 3.4 LC/MS data processing and Statistical Analysis ····························31 CHAPTER 4 Results ···························································33 4.1 Method Optimization ·······················································33 4.2 Method Validation ·························································40 4.3 Patient characteristics ···················································44 4.4 Assessment applying the Naranjo and the CIOMS/RUCAM scales ················50 4.3 Potential biomarkers for detecting hepatotoxicity ·························53 CHAPTER 5 Discussion ························································59 CHAPTER 6 Conclusion ························································64 References ········································································65 | |
| dc.language.iso | en | |
| dc.subject | voriconazole | zh_TW |
| dc.subject | 生物標記 | zh_TW |
| dc.subject | 肝毒性 | zh_TW |
| dc.subject | 肝損傷 | zh_TW |
| dc.subject | 代謝物 | zh_TW |
| dc.subject | voriconazole | en |
| dc.subject | biomarker | en |
| dc.subject | hepatotoxicity | en |
| dc.subject | liver injury | en |
| dc.subject | metabolite | en |
| dc.title | 以液相層析質譜分析法評估voriconazole引起肝臟損傷之潛力生物標記 | zh_TW |
| dc.title | Evaluation of Potential Biomarkers for Voriconazole-Induced Liver Injury by Liquid Chromatography-Mass Spectrometry | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 109-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 郭錦樺(Ching-Hua Kuo) | |
| dc.contributor.oralexamcommittee | 林淑文(Shu-Wen Lin),廖曉偉(Hsiao-Wei Liao) | |
| dc.subject.keyword | 生物標記,肝毒性,肝損傷,代謝物,voriconazole, | zh_TW |
| dc.subject.keyword | biomarker,hepatotoxicity,liver injury,metabolite,voriconazole, | en |
| dc.relation.page | 75 | |
| dc.identifier.doi | 10.6342/NTU202100586 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2021-02-08 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥學研究所 | zh_TW |
| 顯示於系所單位： | 藥學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0502202114375700.pdf 未授權公開取用 | 2.59 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。